KEYNOTE-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
FDA, Food and Drug Administration, KEYTRUDA, Merck, Pembrolizumab, platinum-based chemotherapy
Pembrolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resection and platinum-based chemoth..
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Ventana Medical Systems
Pembrolizumab is approved for advanced endometrial carcinoma
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair de..
Bevacizumab, KEYTRUDA, Merck, PD-L1, Pembrolizumab
Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer
Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration for patients with persistent, recurrent, or metastatic cervical cancer ..
KEYTRUDA, Lenvatinib, Lenvatinib plus pembrolizumab, Lenvima, Merck, renal cell carcinoma
The FDA has approved the combination of lenvatinib and pembrolizumab for advanced renal cell carcinoma
August 2021: The combination of lenvatinib (Lenvima, Eisai) and pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the first-line treatment of adult patients with advanced renal cell carcinom..
KEYTRUDA, Merck, Pembrolizumab, TNBC
Pembrolizumab has been approved by the FDA for high-risk early-stage triple-negative breast cancer
August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment in combination with chemotherapy, and later as a single agent as adjuv..
Eisai, KEYTRUDA, Lenvatinib, Lenvima, Merck, NCT03517449, Pembrolizumab
Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer
August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients with advanced endometrial carcinoma that is not microsatellite instabi..
fluoropyrimidine, gastroesophageal junction (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co, Pembrolizumab, Trastuzumab
Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer
August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been granted accelerated approval by the Food and Drug Administration for the firs..
High tumor burden, Immunotherapy, KEYTRUDA, Pembrolizumab, TMB-H
Pembrolizumab approved for use in any cancer with a high tumor mutational burden
July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorization is f..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA
Pembrolizumab is approved by FDA for adjuvant treatment of melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..